A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma.
about
A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
A phase 2 study of rituximab, ...... rade and mantle cell lymphoma.
@en
A phase 2 study of rituximab, ...... rade and mantle cell lymphoma.
@nl
type
label
A phase 2 study of rituximab, ...... rade and mantle cell lymphoma.
@en
A phase 2 study of rituximab, ...... rade and mantle cell lymphoma.
@nl
prefLabel
A phase 2 study of rituximab, ...... rade and mantle cell lymphoma.
@en
A phase 2 study of rituximab, ...... rade and mantle cell lymphoma.
@nl
P2093
P2860
P50
P1433
P1476
A phase 2 study of rituximab, ...... rade and mantle cell lymphoma.
@en
P2093
Brenda F Ginos
Christopher R Conley
Craig B Reeder
Craig S Nichols
David J Inwards
Donald W Northfelt
Heidi E Kosiorek
Jose F Leis
Katherine M Gano
Patrick B Johnston
P2860
P304
P356
10.1080/10428194.2017.1416368
P577
2018-01-10T00:00:00Z